Tracking treatment pathways in adult patients with hyperkalemia (V1.0)

• Research type

  Research Study

• Full title

  Tracking treatment pathways in adult patients with hyperkalemia (TRACK) A prospective, non-interventional, longitudinal study of the treatment journey of adult patients with hyperkalemia

• IRAS ID

  318105

• Contact name

  Albert Power

• Contact email

  albert.power@nbt.nhs.uk

• Sponsor organisation

  AstraZeneca

• Duration of Study in the UK

  1 years, 7 months, 26 days

• Research summary

  Contemporary real-world evidence (RWE) on the rationale for treatment decisions for hyperkalemia (HK) is scarce. Most studies only describe the patient characteristics and management of HK retrospectively and lack information on healthcare providers (HCP) decision-making processes. This observational study aims to increase the understanding of HK management, treatment patterns, and the treatment decision-making process for the management of patients with HK over a period of up to 12 months. The generation of real-world evidence (RWE) to understand the treatment management decision rationale and to prospectively describe patient characteristics, treatment management patterns among patients with HK is of importance to improve adherence to guidelines and improve patient care.

• REC name

  London - Brighton & Sussex Research Ethics Committee

• REC reference

  22/PR/1248

• Date of REC Opinion

  14 Oct 2022

• REC opinion

  Further Information Favourable Opinion